We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Johnson & Johnson (JNJ) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Read MoreHide Full Article
Johnson & Johnson (JNJ - Free Report) closed at $267.66 in the latest trading session, marking a -1.58% move from the prior day. The stock's performance was behind the S&P 500's daily loss of 0.17%. Elsewhere, the Dow saw a downswing of 0.26%, while the tech-heavy Nasdaq depreciated by 0.09%.
The world's biggest maker of health care products's shares have seen an increase of 2.29% over the last month, surpassing the Medical sector's loss of 0.67% and the S&P 500's loss of 0.24%.
The upcoming earnings release of Johnson & Johnson will be of great interest to investors. The company's earnings report is expected on October 13, 2026. On that day, Johnson & Johnson is projected to report earnings of $2.96 per share, which would represent year-over-year growth of 5.71%. In the meantime, our current consensus estimate forecasts the revenue to be $25.36 billion, indicating a 5.71% growth compared to the corresponding quarter of the prior year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $11.61 per share and a revenue of $101.13 billion, signifying shifts of +7.6% and +7.37%, respectively, from the last year.
Investors might also notice recent changes to analyst estimates for Johnson & Johnson. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.01% decrease. Johnson & Johnson is currently sporting a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Johnson & Johnson has a Forward P/E ratio of 23.43 right now. This denotes a premium relative to the industry average Forward P/E of 16.57.
It's also important to note that JNJ currently trades at a PEG ratio of 2.6. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. JNJ's industry had an average PEG ratio of 2.17 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 110, putting it in the top 45% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Johnson & Johnson (JNJ) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Johnson & Johnson (JNJ - Free Report) closed at $267.66 in the latest trading session, marking a -1.58% move from the prior day. The stock's performance was behind the S&P 500's daily loss of 0.17%. Elsewhere, the Dow saw a downswing of 0.26%, while the tech-heavy Nasdaq depreciated by 0.09%.
The world's biggest maker of health care products's shares have seen an increase of 2.29% over the last month, surpassing the Medical sector's loss of 0.67% and the S&P 500's loss of 0.24%.
The upcoming earnings release of Johnson & Johnson will be of great interest to investors. The company's earnings report is expected on October 13, 2026. On that day, Johnson & Johnson is projected to report earnings of $2.96 per share, which would represent year-over-year growth of 5.71%. In the meantime, our current consensus estimate forecasts the revenue to be $25.36 billion, indicating a 5.71% growth compared to the corresponding quarter of the prior year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $11.61 per share and a revenue of $101.13 billion, signifying shifts of +7.6% and +7.37%, respectively, from the last year.
Investors might also notice recent changes to analyst estimates for Johnson & Johnson. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.01% decrease. Johnson & Johnson is currently sporting a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Johnson & Johnson has a Forward P/E ratio of 23.43 right now. This denotes a premium relative to the industry average Forward P/E of 16.57.
It's also important to note that JNJ currently trades at a PEG ratio of 2.6. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. JNJ's industry had an average PEG ratio of 2.17 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 110, putting it in the top 45% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.